|
1.
|
Folkerd EJ and Dowsett M: Influence of sex
hormones on cancer progression. J Clin Oncol. 28:4038–4044. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Martin L, Coffey M, Lawler M, Hollywood D
and Marignol L: DNA mismatch repair and the transition to hormone
independence in breast and prostate cancer. Cancer Lett.
291:142–149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Xu Y and Price BD: Chromatin dynamics and
the repair of DNA double strand breaks. Cell Cycle. 10:261–267.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Crasta K, Ganem NJ, Dagher R, Lantermann
AB, Ivanova EV, Pan Y, et al: DNA breaks and chromosome
pulverization from errors in mitosis. Nature. 482:53–58. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Rodriguez GP, Romanova NV, Bao G, Rouf NC,
Kow YW and Crouse GF: Mismatch repair-dependent mutagenesis in
nondividing cells. Proc Natl Acad Sci USA. 109:6153–6158. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Vurusaner B, Poli G and Basaga H: Tumor
suppressor genes and ROS: complex networks of interactions. Free
Radic Biol Med. 52:7–18. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Hanel W and Moll UM: Links between mutant
p53 and genomic instability. J Cell Biochem. 113:433–439. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Jones RM and Petermann E: Replication fork
dynamics and the DNA damage response. Biochem J. 443:13–26. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Smith J, Tho LM, Xu N and Gillespie DA:
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and
cancer. Adv Cancer Res. 108:73–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Hennequin C, Quero L and Favaudon V: DNA
repair and tumour radiosensitivity: focus on ATM gene. Bull Cancer.
98:239–246. 2011.PubMed/NCBI
|
|
11.
|
Molchadsky A, Rivlin N, Brosh R, Rotter V
and Sarig R: p53 is balancing development, differentiation and
de-differentiation to assure cancer prevention. Carcinogenesis.
31:1501–1508. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Muller PA, Vousden KH and Norman JC: p53
and its mutants in tumor cell migration and invasion. J Cell Biol.
192:209–218. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Essmann F and Schulze-Osthoff K:
Translational approaches targeting the p53 pathway for anti-cancer
therapy. Br J Pharmacol. 165:328–344. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Karve TM, Li X and Saha T: BRCA1-mediated
signaling pathways in ovarian carcinogenesis. Funct Integr
Genomics. 12:63–79. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Berstein LM: Endocrinology of the wild and
mutant BRCA1 gene and types of hormonal carcinogenesis. Future
Oncol. 4:23–39. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Okumura N, Yoshida H, Kitagishi Y,
Nishimura Y and Matsuda S: Alternative splicings on p53, BRCA1 and
PTEN genes involved in breast cancer. Biochem Biophys Res Commun.
413:395–399. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Mueck AO and Sitruk-Ware R: Nomegestrol
acetate, a novel progestogen for oral contraception. Steroids.
76:531–539. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Bolton JL and Thatcher GR: Potential
mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol.
21:93–101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Comstock CE and Knudsen KE: The complex
role of AR signaling after cytotoxic insult: implications for
cell-cycle-based chemotherapeutics. Cell Cycle. 6:1307–1313. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Lu S, Becker KA, Hagen MJ, Yan H, Roberts
AL, Mathews LA, et al: Transcriptional responses to estrogen and
progesterone in mammary gland identify networks regulating p53
activity. Endocrinology. 149:4809–4820. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Golubovskaya VM, Conway-Dorsey K, Edmiston
SN, Tse CK, Lark AA, Livasy CA, et al: FAK overexpression and p53
mutations are highly correlated in human breast cancer. Int J
Cancer. 125:1735–1738. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Anaganti S, Fernández-Cuesta L, Langerød
A, Hainaut P and Olivier M: p53-Dependent repression of focal
adhesion kinase in response to estradiol in breast cancer
cell-lines. Cancer Lett. 300:215–224. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Lee HJ, Chattopadhyay S, Yoon WH, Bahk JY,
Kim TH, Kang HS, et al: Overexpression of hepatocyte nuclear
factor-3alpha induces apoptosis through the upregulation and
accumulation of cytoplasmic p53 in prostate cancer cells. Prostate.
70:353–361. 2010.PubMed/NCBI
|
|
24.
|
Ide H, Tokiwa S, Sakamaki K, Nishio K,
Isotani S, Muto S, et al: Combined inhibitory effects of soy
isoflavones and curcumin on the production of prostate-specific
antigen. Prostate. 70:1127–1133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Welsh J: Cellular and molecular effects of
vitamin D on carcinogenesis. Arch Biochem Biophys. 523:107–114.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Ting HJ, Yasmin-Karim S, Yan SJ, Hsu JW,
Lin TH, Zeng W, et al: A positive feedback signaling loop between
ATM and the vitamin D receptor is critical for cancer
chemoprevention by vitamin D. Cancer Res. 72:958–968. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Kelly GL and Strasser A: The essential
role of evasion from cell death in cancer. Adv Cancer Res.
111:39–96. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Natarajan AT and Palitti F: DNA repair and
chromosomal alterations. Mutat Res. 657:3–7. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Bhatti S, Kozlov S, Farooqi AA, Naqi A,
Lavin M and Khanna KK: ATM protein kinase: the linchpin of cellular
defenses to stress. Cell Mol Life Sci. 68:2977–3006. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Okumura N, Yoshida H, Kitagishi Y,
Nishimura Y, Iseki S and Matsuda S: Against lung cancer cells: to
be, or not to be, that is the problem. Lung Cancer Int. View Article : Google Scholar : 2012. View Article : Google Scholar
|
|
31.
|
Gigek CO, Chen ES, Calcagno DQ, Wisnieski
F, Burbano RR and Smith MA: Epigenetic mechanisms in gastric
cancer. Epigenomics. 4:279–294. 2012. View Article : Google Scholar
|
|
32.
|
Martinez-Rivera M and Siddik ZH:
Resistance and gain-of-resistance phenotypes in cancers harboring
wild-type p53. Biochem Pharmacol. 83:1049–1062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Stegh AH: Targeting the p53 signaling
pathway in cancer therapy - the promises, challenges and perils.
Expert Opin Ther Targets. 16:67–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Kim DH, Kundu JK and Surh YJ: Redox
modulation of p53: mechanisms and functional significance. Mol
Carcinog. 50:222–234. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Gartel AL: p21(WAF1/CIP1) and cancer: a
shifting paradigm? Biofactors. 35:161–164. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Ocker M and Schneider-Stock R: Histone
deacetylase inhibitors: signalling towards p21cip1/waf1. Int J
Biochem Cell Biol. 39:1367–1374. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Osborne MP: Chemoprevention of breast
cancer. Surg Clin North Am. 79:1207–1221. 1999. View Article : Google Scholar
|
|
38.
|
Roy R, Chun J and Powell SN: BRCA1 and
BRCA2: different roles in a common pathway of genome protection.
Nat Rev Cancer. 12:68–78. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Prado A, Andrades P and Parada F: Recent
developments in the ability to predict and modify breast cancer
risk. J Plast Reconstr Aesthet Surg. 63:1581–1587. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Ohta T, Sato K and Wu W: The BRCA1
ubiquitin ligase and homologous recombination repair. FEBS Lett.
585:2836–2844. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Leung CC and Glover JN: BRCT domains: easy
as one, two, three. Cell Cycle. 10:2461–2470. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Ouchi T: BRCA1 phosphorylation: biological
consequences. Cancer Biol Ther. 5:470–475. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Kotsopoulos J and Narod SA: Androgens and
breast cancer. Steroids. 77:1–9. 2012. View Article : Google Scholar
|
|
44.
|
Dumitrescu RG: Epigenetic markers of early
tumor development. Methods Mol Biol. 863:3–14. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Centrella M and McCarthy TL: Estrogen
receptor dependent gene expression by osteoblasts - direct,
indirect, circumspect, and speculative effects. Steroids.
77:174–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Wada-Hiraike O, Yano T, Nei T, Matsumoto
Y, Nagasaka K, Takizawa S, et al: The DNA mismatch repair gene
hMSH2 is a potent coactivator of oestrogen receptor alpha. Br J
Cancer. 92:2286–2291. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Murphy LC and Leygue E: The role of
estrogen receptor-β in breast cancer. Semin Reprod Med. 30:5–13.
2012.
|
|
48.
|
Warner M and Gustafsson JA: The role of
estrogen receptor beta (ERbeta) in malignant diseases - a new
potential target for antiproliferative drugs in prevention and
treatment of cancer. Biochem Biophys Res Commun. 396:63–66. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Lamartiniere CA: Timing of exposure and
mammary cancer risk. J Mammary Gland Biol Neoplasia. 7:67–76. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Shaik AP, Jamil K and Das P: CYP1A1
polymorphisms and risk of prostate cancer: a meta-analysis. Urol J.
6:78–86. 2009.PubMed/NCBI
|
|
51.
|
Cancel-Tassin G and Cussenot O: Prostate
cancer genetics. Minerva Urol Nefrol. 57:289–300. 2005.
|
|
52.
|
Agoulnik IU and Weigel NL: Androgen
receptor action in hormone-dependent and recurrent prostate cancer.
J Cell Biochem. 99:362–372. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Purohit A and Foster PA: Steroid sulfatase
inhibitors for estrogen- and androgen-dependent cancers. J
Endocrinol. 212:99–110. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Banerjee S, Li Y, Wang Z and Sarkar FH:
Multi-targeted therapy of cancer by genistein. Cancer Lett.
69:226–242. 2008. View Article : Google Scholar
|
|
55.
|
Park S and Choi J: Inhibition of
beta-catenin/Tcf signaling by flavonoids. J Cell Biochem.
110:1376–1385. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Power KA and Thompson LU: Can the
combination of flaxseed and its lignans with soy and its
isoflavones reduce the growth stimulatory effect of soy and its
isoflavones on established breast cancer? Mol Nutr Food Res.
51:845–856. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Sánchez Y, Amrán D, Fernández C, de Blas E
and Aller P: Genistein selectively potentiates arsenic
trioxide-induced apoptosis in human leukemia cells via reactive
oxygen species generation and activation of reactive oxygen
species-inducible protein kinases (p38-MAPK, AMPK). Int J Cancer.
123:1205–1214. 2008.
|
|
58.
|
Langeberg WJ, Kwon EM, Koopmeiners JS,
Ostrander EA and Stanford JL: Population-based study of the
association of variants in mismatch repair genes with prostate
cancer risk and outcomes. Cancer Epidemiol Biomarkers Prev.
19:258–264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59.
|
Lacroix-Triki M, Lambros MB, Geyer FC,
Suarez PH, Reis-Filho JS and Weigelt B: Absence of microsatellite
instability in mucinous carcinomas of the breast. Int J Clin Exp
Pathol. 27:22–31. 2010.
|
|
60.
|
Norris AM, Woodruff RD, D’Agostino RB Jr,
Clodfelter JE and Scarpinato KD: Elevated levels of the mismatch
repair protein PMS2 are associated with prostate cancer. Prostate.
67:214–225. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61.
|
Chen Y, Wang J, Fraig MM, Henderson K,
Bissada NK, Watson DK, et al: Alterations in PMS2, MSH2 and MLH1
expression in human prostate cancer. Int J Oncol. 22:1033–1043.
2003.PubMed/NCBI
|
|
62.
|
Van Poppel H and Tombal B: Chemoprevention
of prostate cancer with nutrients and supplements. Cancer Manag
Res. 3:91–100. 2011.PubMed/NCBI
|
|
63.
|
Kristal AR, Arnold KB, Neuhouser ML,
Goodman P, Platz EA, Albanes D, et al: Diet, supplement use, and
prostate cancer risk: results from the prostate cancer prevention
trial. Am J Epidemiol. 172:566–577. 2010. View Article : Google Scholar : PubMed/NCBI
|
